Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775063 | 0.83 | DRD2 (0.46) | RIPK1MAOAMAOBALDH1A1CHRNA7 | |
| SCHEMBL17358800 | 0.82 | RIPK1 (0.61) | RIPK1MAOAMAOBPDE5ATSHR | |
| SCHEMBL17358798 | 0.82 | RIPK1 (0.61) | RIPK1MAOAMAOBPDE5ATSHR | |
| SCHEMBL23032154 | 0.81 | PRKCZ (0.40) | ALDH1A1CHRNA7 | |
| SCHEMBL23032156 | 0.81 | PRKCZ (0.40) | ALDH1A1CHRNA7 | |
| SCHEMBL22473219 | 0.80 | CHRNB2 (0.59) | RIPK1CHRNA7 | |
| SCHEMBL22473392 | 0.80 | CHRNB2 (0.59) | RIPK1CHRNA7 | |
| SCHEMBL13388673 | 0.80 | CHRNB2 (0.59) | RIPK1CHRNA7 | |
| SCHEMBL24775494 | 0.80 | SLC6A2 (0.46) | ALDH1A1PDE5ATSHR | |
| SCHEMBL13162079 | 0.80 | CHRNB2 (0.64) | ALDH1A1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | RIPK1 326/4885MAOA 3912/4885MAOB 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.